

MCT

Molecular Cancer Therapeutics

Articles

- 981–987 **The Apoptotic Effect of HA14-1, a Bcl-2-interacting Small Molecular Compound, Requires Bax Translocation and Is Enhanced by PK11195**
Jun Chen, Angela Freeman, Jihua Liu, Qiang Dai, and Ruey-min Lee
- 989–997 **Inhibition of the Phosphatidylinositol 3'-Kinase-AKT Pathway Induces Apoptosis in Pancreatic Carcinoma Cells *in Vitro* and *in Vivo***
Victor M. Bondar, Bridget Sweeney-Gotsch, Michael Andreeff, Gordon B. Mills, and David J. McConkey
- 999–1007 **Intratumor Administration of Interleukin 13 Receptor-targeted Cytotoxin Induces Apoptotic Cell Death in Human Malignant Glioma Tumor Xenografts**
Mariko Kawakami, Koji Kawakami, and Raj K. Puri
- 1009–1017 **A Novel Mechanism by Which *N*-(4-hydroxyphenyl)retinamide Inhibits Breast Cancer Cell Growth: The Production of Nitric Oxide**
Ann-Marie Simeone, Suhendan Ekmekcioglu, Lyle D. Broemeling, Elizabeth A. Grimm, and Ana M. Tari
- 1019–1024 **Glycoinositol Phospholipid-anchored Interleukin 2 but not Secreted Interleukin 2 Inhibits Melanoma Tumor Growth in Mice**
Jianfei Ji, Jinhua Li, Lillia M. Holmes, Kelly E. Burgin, Xianzhong Yu, Thomas E. Wagner, and Yanzhang Wei
- 1025–1033 **Cell Proliferation in the Normal Mouse Mammary Gland and Inhibition by Phenylbutyrate**
Catherine Kennedy, Karen Byth, Christine L. Clarke, and Anna deFazio
- 1035–1042 **Prediction of Chemosensitivity for Patients with Acute Myeloid Leukemia, According to Expression Levels of 28 Genes Selected by Genome-wide Complementary DNA Microarray Analysis**
Jun-ichi Okutsu, Tatsuhiko Tsunoda, Yasuyuki Kaneta, Toyomasa Katagiri, Osamu Kitahara, Hitoshi Zembutsu, Rempei Yanagawa, Shuichi Miyawaki, Kazutaka Kuriyama, Nobuyuki Kubota, Yukihiro Kimura, Kohmei Kubo, Fumiharu Yagasaki, Toshio Higa, Hirokuni Taguchi, Tadasu Tobita, Hideki Akiyama, Akihiro Takeshita, Yan-Hua Wang, Toshiko Motoji, Ryuzo Ohno, and Yusuke Nakamura

Articles (cont'd)

- 1043–1049 **Development of p53 Protein Transduction Therapy Using Membrane-permeable Peptides and the Application to Oral Cancer Cells** Toshihiko Takenobu, Kazuhito Tomizawa, Masayuki Matsushita, Sheng-Tian Li, Akiyoshi Moriwaki, Yun-Fei Lu, and Hideki Matsui
- 1051–1058 **X-linked Inhibitor of Apoptosis (XIAP) Blocks Apo2 Ligand/Tumor Necrosis Factor-related Apoptosis-inducing Ligand-mediated Apoptosis of Prostate Cancer Cells in the Presence of Mitochondrial Activation: Sensitization by Overexpression of Second Mitochondria-derived Activator of Caspase/Direct IAP-binding Protein with Low pI (Smac/DIABLO)** Chuen-Pei Ng and Benjamin Bonavida
- 1059–1066 **Distinct Effects of Methylseleninic Acid versus Selenite on Apoptosis, Cell Cycle, and Protein Kinase Pathways in DU145 Human Prostate Cancer Cells** Cheng Jiang, Zaisen Wang, Howard Ganther, and Junxuan Lü
- 1067–1078 **A Novel Indolocarbazole, ICP-1, Abrogates DNA Damage-induced Cell Cycle Arrest and Enhances Cytotoxicity: Similarities and Differences to the Cell Cycle Checkpoint Abrogator UCN-01** Alan Eastman, Ethan A. Kohn, Mary Kay Brown, Joerg Rathman, Mark Livingstone, David H. Blank, and Gordon W. Gribble
- 1079–1087 **Selenium Compounds Inhibit I κ B Kinase (IKK) and Nuclear Factor- κ B (NF- κ B) in Prostate Cancer Cells** Alexander V. Gasparian, Ya Juan Yao, Junxuan Lü, Alexander Y. Yemelyanov, Lyudmila A. Lyakh, Thomas J. Slaga, and Irina V. Budunova
- 1089–1095 **Efficacy of a Glutathione S-Transferase π -activated Prodrug in Platinum-resistant Ovarian Cancer Cells** Danyelle M. Townsend, Hongxie Shen, Alexandra L. Staros, Laurent Gaté, and Kenneth D. Tew
- 1097–1104 **MDM2 Does Not Influence p53-mediated Sensitivity to DNA-damaging Drugs** Pamela P. McKenzie, Christina R. McPake, Amy A. Ashford, Elio F. Vanin, and Linda C. Harris
- 1105–1114 **Comparative Study of the Importance of Multidrug Resistance-associated Protein 1 and P-Glycoprotein to Drug Sensitivity in Immortalized Mouse Embryonic Fibroblasts** Z. Ping Lin, Dennis R. Johnson, Rick A. Finch, Martin G. Belinsky, Gary D. Kruh, and Alan C. Sartorelli

Articles (cont'd)

- 1115–1124 **Juxtamembrane Mutant V560GKit Is More Sensitive to Imatinib (STI571) Compared with Wild-Type c-Kit Whereas the Kinase Domain Mutant D816VKit Is Resistant** Michelle J. Frost, Petranell T. Ferrao, Timothy P. Hughes, and Leonie K. Ashman
- 1125–1128 **Inhibition of Mitogen-activated Protein Kinase Activity of Human Lymphocytes after Oral Administration of Oltipraz** Burra V. Madhukar, Nikolay V. Dimitrov, Cheryl Meyer-Leece, Margarita L. Contreras, and James Crowell
- 1129–1137 **Attenuated Recombinant Vaccinia Virus Expressing Oncofetal Antigen (Tumor-associated Antigen) 5T4 Induces Active Therapy of Established Tumors** Kate Mulryan, Matthew G. Ryan, Kevin A. Myers, David Shaw, Who Wang, Susan M. Kingsman, Peter L. Stern, and Miles W. Carroll
- 1139–1145 **Induction of Thymidine Phosphorylase in Both Irradiated and Shielded, Contralateral Human U87MG Glioma Xenografts: Implications for a Dual Modality Treatment Using Capecitabine and Irradiation** Carmelo Blanquicett, G. Yancey Gillespie, L. Burt Nabors, C. Ryan Miller, Sumen Bharara, Donald J. Buchsbaum, Robert. B. Diasio, and Martin R. Johnson

Minireview

- 1147–1151 **Overcoming Immune Tolerance to Cancer by Heat Shock Protein Vaccines** Bei Liu, Anna M. DeFilippo, and Zihai Li

i-ii Instructions for Authors

In this issue: 94th AACR Annual Meeting Call for Abstracts

The Cover

Poly-arginine peptide has the ability of protein transduction. The protein delivery system using eleven poly-arginine peptides (11R) is a powerful tool for the transduction of the biologically active tumor suppressor protein, p53, to suppress the proliferation of oral cancer cells.

The 11R-fused p53 proteins (11R-p53) effectively penetrated across the plasma membrane of SAOS-2 cells and translocated into the nucleus. The 11R-p53 is indicated by *green staining* and tubulin by *red staining*. For details, see *Takenobu et al.* in this issue.
